ERBB2 and breast cancer: Patients with HER2- overexpressing breast cancer benefit from HER2-targeted therapy, including anti-HER2 antibodies (such as trastuzumab and pertuzumab) and small-molecule tyrosine kinase inhibitors (such as lapatinib and neratinib) [9].